Device Trial Radar · NCT06999304
Pilot TMS in Mild TBI
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jun 18, 2025
Primary completion
Apr 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- HealthPartners InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 31, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Persistent post-concussive symptoms (PPCS) involve an array of physical, cognitive, and behavioral symptoms lasting more than a month after mild traumatic brain injury (mTBI). 34-44% of people with mTBI or concussion present with a considerable burden of PPCS 3-6 months after injury. There is currently no standardized treatment for PPCS, nor FDA approved medication for any neuropsychiatric or neurocognitive symptoms associated with mTBI. Transcranial magnetic stimulation (TMS) shows promise as a treatment for PPCS; however, the current one-size-fits-all approach does not address the heterogeneity of symptoms. We propose utilization of resting state functional MRI (rs-fMRI) guided rTMS to target personalized brain networks burdened with PPCS.
Conditions
- Persistent Post Concussive Headache
- Mild Traumatic Brain Injury
Interventions
Intermittent theta burst stimulationDevice
MagVenture TMS Therapy active coil with theta burst stimulation. Resting motor threshold: 80%; Intermittent theta burst - Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz; Continuous theta burst - Number of pulses per session: 1800 pulses; Pulse frequency in burst: 50 Hertz
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with anomalous parcellations - developing the method of personalization of TMS for PPCSTime frame: baseline
- Anomalous parcellations - developing the method of personalization of TMS targets for PPCSTime frame: baseline
- Distribution of complaints for PPCSTime frame: baseline
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
HealthPartners Neuroscience Center
Saint Paul, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.